Medicalgorithmics, a WSE-listed medtech company, estimates that its newly secured ECG service contracts supported by proprietary AI-powered software will generate a stable monthly recurring revenue (MRR) stream of approximately USD 160.2K (around PLN 593K). This estimate does not yet include revenues from the new U.S.-based IDTF client announced in February this year. Notably, 66% of the increase in the new client portfolio’s value is attributable to the U.S. market. The company’s cutting-edge AI software continues to gain significant traction, and Medicalgorithmics is actively onboarding additional clients and pursuing further business development opportunities.
“The growth in recurring monthly revenue from newly acquired clients clearly demonstrates the accelerating momentum of our business. Importantly, the presented monthly revenue estimate does not yet include the major U.S. IDTF client secured earlier this year, where we anticipate further significant scaling. We expect the sales velocity of our innovative AI software to continue increasing in line with our strategic growth roadmap, further driven by additional client activations. Conservatively, we estimate that this portfolio of 8 new clients alone will generate over PLN 7 million (USD ~1.9 million) in revenue over the next 12 months,” said Dr. Kris Siemionow, CEO of Medicalgorithmics. “It is worth emphasizing that over the past 18 months we have signed 27 contracts, currently at various stages of onboarding and integration. Simultaneously, we continue to expand our commercial footprint by targeting both existing and new high-potential markets that support rapid technology adoption,” he added.
Based on historical revenue performance and current growth dynamics, Medicalgorithmics has published an estimate outlining the expected recurring revenue stream from the 8 newly commercialized client contracts over the next twelve months. The total portfolio value has been estimated at USD 160.2K in average monthly recurring revenue, translating to approximately USD 1.9 million (PLN 7.1 million) in cumulative revenue between August 2025 and July 2026.
The year 2025 marks a significant uptick in global interest in the company’s solutions and an acceleration in customer acquisition. Since the beginning of the year, Medicalgorithmics has executed 14 new commercial agreements – surpassing the total for all of 2024. These include the first commercial contract for VCAST, a strategic milestone that expands the company’s presence in the Scandinavian market. As of the end of July, Medicalgorithmics had successfully integrated 28% (4 out of 14) of the new clients signed in 2025. The onboarding of additional accounts, including a European IDTF, has contributed to a 33% year-over-year increase in revenue for July.